NASDAQ:IMCC - Nasdaq - CA44969Q4060 - Common Stock - Currency: USD
IMCC gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of IMCC have multiple concerns. While showing a medium growth rate, IMCC is valued expensive at the moment.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -27.01% | ||
ROE | -201.89% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 15.64% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 3.01 | ||
Debt/FCF | N/A | ||
Altman-Z | -8.69 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.67 | ||
Quick Ratio | 0.58 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
NASDAQ:IMCC (5/2/2025, 8:02:13 PM)
1.73
+0.04 (+2.37%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 0.14 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 1.41 | ||
P/tB | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -27.01% | ||
ROE | -201.89% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 15.64% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 3.01 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 7.14% | ||
Cap/Sales | 0.29% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 0.67 | ||
Quick Ratio | 0.58 | ||
Altman-Z | -8.69 |